Epithalamin
Also known as: Epithalamine · Epitalamin · Pineal gland polypeptide extract · Pineal peptide preparation (epiphyseal bioregulator) · Cytogen / 'Epiphysamine' family preparation (Khavinson group) · Precursor extract of synthetic Epitalon (AEDG, Ala-Glu-Asp-Gly)
Research focus
Pineal gland / neuroendocrine and circadian system; geroprotection (melatonin rhythm, immune and cardiovascular aging, oxidative stress)
US regulatory status
Not FDA-approved · Not compoundable
Evidence rating
Emerging
Origin
Epithalamin is a low-molecular-weight polypeptide complex extracted from the pineal gland (epiphysis), originally of cattle (bovine/calf) pineal tissue. It traces to Soviet-era work begun in the 1970s associated with Vladimir Dilman and Vladimir Khavinson, and was developed and studied for decades primarily at what became the St. Petersburg Institute of Bioregulation and Gerontology (North-Western Branch of the Russian Academy of Medical Sciences), in collaboration with the N.N. Petrov Research Institute of Oncology (St. Petersburg) and the Institute of Gerontology of the Academy of Medical Sciences of Ukraine (Kiev). It is one of the "peptide bioregulator" tissue extracts in the Khavinson program. Notably, Epithalamin is the natural extract from which the synthetic tetrapeptide Epitalon (Epithalon; Ala-Glu-Asp-Gly / AEDG) was later derived, with the synthetic peptide designed around amino-acid composition attributed to this pineal complex. Because it is a tissue-derived mixture rather than a synthetic single molecule, "Epithalamin" denotes a preparation, not one defined sequence.
Plain-language summary
Epithalamin is not a single peptide but a mixture of small proteins pulled from animal pineal glands (the brain's melatonin-making organ). Russian and Ukrainian gerontology researchers have studied it since the 1970s as an "anti-aging" preparation, and it is the natural extract that inspired the better-known synthetic peptide Epitalon. Most of the evidence is preclinical: in fruit flies, mice, and rats, the same research group reported longer average lifespans, lower oxidative-stress markers, and in some experiments fewer tumors. There are also small human geriatric studies (mostly in older adults with cardiovascular aging) reporting that it nudged night-time melatonin and circadian rhythms back toward a more youthful pattern. The big caveat: nearly all of this comes from one connected group of investigators, the human studies are small and largely unblinded, and there is no large, independent, randomized replication in peer-reviewed English-language literature. So Epithalamin is best understood as an interesting but unproven historical research preparation, not a validated therapy.
Claimed mechanism (as reported)
The Khavinson group's published work proposes that Epithalamin acts as a pineal "bioregulator" that reportedly stimulates the synthesis and night-time secretion of endogenous melatonin and helps restore age-disrupted circadian rhythms. Additional proposed mechanisms in the literature include antioxidant activity (reported increases in superoxide dismutase and catalase activity and reduced lipid/protein peroxidation in animal tissues in studies) and modulation of immune and neuroendocrine function. As a tissue extract its active constituents are not fully defined, and the synthetic peptide Epitalon was created as a candidate "active fragment." These mechanisms remain an area of investigation and are supported mainly by in-vitro and animal work from a single research network; they should be read as proposed rather than established.
Evidence summary
Relative to most Khavinson-group preparations, Epithalamin has an unusually long paper trail (roughly 100 PubMed-indexed records spanning the 1980s to the 2010s), including a substantial preclinical record in fruit flies, mice, and rats (reported lifespan extension, antioxidant effects, and tumor-incidence findings) and several small human geriatric studies, two of which are indexed as randomized/controlled. However, the literature is dominated by a single interconnected research network (Anisimov, Khavinson, Morozov, Korkushko, Shatilo and colleagues, across St. Petersburg and Kiev), published largely in Russian-language or Russian gerontology journals. Human cohorts are small, mostly open-label or weakly blinded, and the headline outcomes (reduced mortality over multi-year follow-up, normalized melatonin rhythm) have not been independently replicated in large, blinded, registered trials. There is therefore some published human data, but it is not sufficient to establish efficacy. Graded Theoretical. None of this should be read as proof that Epithalamin improves health outcomes in people. A multi-source review confirmed Epithalamin has more human data than most bioregulators: a 12-year randomized, placebo-controlled trial in elderly coronary-disease patients reported ~28% lower all-cause and ~2-fold lower cardiovascular mortality (Korkushko/Khavinson, 2006), and a 266-subject 6–8-year controlled study reported reduced mortality with thymic+pineal peptides (Khavinson & Morozov, 2003). An independent Alzheimer’s Drug Discovery Foundation appraisal (2015) judged the human evidence limited and single-group. No trials are registered on ClinicalTrials.gov.
What the research reports
Twenty years of study on effects of pineal peptide preparation: epithalamin in experimental gerontology and oncology
Grade CAnisimov VN, Khavinson VKh, Morozov VG · Annals of the New York Academy of Sciences · 1994 (reviewing ~1974–1994)
Reported finding: Summarizes two decades of single-group research reporting that the pineal extract reportedly influenced reproductive, immune and neuroendocrine aging and tumor incidence in laboratory animals. Presented as the group's own program, without independent confirmation.
Sample: Review summarizing many rodent and experimental cohorts (varied n)
Methodology: C — narrative review of one group's animal/experimental work; no independent replication, preclinical and early-clinical mix
Limitations: Author-group review, not a primary controlled study; selection and publication bias likely; little blinding or external replication.
Pineal peptide preparation epithalamin increases the lifespan of fruit flies, mice and rats
Grade CAnisimov VN, Mylnikov SV, Khavinson VK · Mechanisms of Ageing and Development · 1998
Reported finding: Reported mean-lifespan increases of roughly 11–31% across species and reduced mortality rate, attributed by the authors to increased melatonin secretion and reduced free-radical processes. Reported without independent replication.
Sample: Multiple cohorts of D. melanogaster, SHR and C3H/Sn mice, and LIO rats
Methodology: C — animal lifespan study, single research group, English-language journal
Limitations: Single-group animal work; surrogate aging endpoints; species-specific results; no human relevance established.
Peptide geroprotector from the pituitary gland inhibits rapid aging of elderly people: results of 15-year follow-up
Grade CKorkushko OV, Khavinson VKh, Shatilo VB, Antonyk-Sheglova IA · Bulletin of Experimental Biology and Medicine · 2000–2011 (15-year follow-up)
Reported finding: Over 3 years of courses on top of standard cardiac therapy, the authors reported slower cardiovascular aging, preserved physical endurance, normalized melatonin rhythm, and lower mortality across long-term follow-up versus controls. Reported by a single group without independent replication.
Sample: n≈79 (≈39 epithalamin + basic therapy vs ≈40 control)
Methodology: C — small randomized comparative geriatric cohort, single group, limited blinding, long but loosely controlled follow-up
Limitations: Small sample, open-label add-on design, single research network, mortality as a soft long-term endpoint; not independently replicated.
Effect of peptide preparation epithalamin on circadian rhythm of epiphyseal melatonin-producing function in elderly people
Grade CKorkushko OV, Khavinson VKh, Shatilo VB, Magdich LV · Bulletin of Experimental Biology and Medicine · 2004
Reported finding: A treatment course reportedly modulated melatonin output — raising night-time plasma melatonin in subjects with initially low pineal activity while tending to lower it where baseline function was normal. A melatonin-rhythm (surrogate) outcome, not a clinical disease endpoint.
Sample: Small cohort of healthy elderly subjects (tens of participants)
Methodology: C — small geriatric study indexed as randomized/clinical trial, single group, surrogate endpoint
Limitations: Small sample; surrogate biomarker rather than health outcome; single-group; minimal blinding detail; no independent replication.
Geroprotective effect of epithalamine in elderly subjects with accelerated aging (12-year randomized trial)
Grade CKorkushko OV, Khavinson VKh, Shatilo VB, Antonyuk-Shcheglova IA · Bulletin of Experimental Biology and Medicine · 2006
Reported finding: Over 12 years, epithalamine-treated patients were reported to have ~28% lower all-cause mortality and roughly 2-fold lower cardiovascular mortality than controls on the same basic therapy, with improved exercise tolerance.
Sample: ~79 elderly coronary-disease patients (~39 epithalamine + 40 control), 6 courses over 3 years, followed 12 years
Methodology: C — genuinely randomized and placebo-controlled with a 12-year hard mortality endpoint, but small and from the originating institute with unblinded outcome reporting
Limitations: Single originating institute; small sample; open-label outcome ascertainment; not independently replicated.
Peptides of pineal gland and thymus prolong human life (266-subject controlled study)
Grade CKhavinson VKh, Morozov VG · Neuroendocrinology Letters · 2003
Reported finding: Thymalin and/or Epithalamin were reported to reduce mortality 1.6-4.1-fold versus control over 6-8 years, alongside lower respiratory-infection and cardiovascular-event incidence.
Sample: n=266 people aged >60; peptides given in the first 2-3 years, observed 6-8 years
Methodology: C/D — controlled long-term study (PubMed-tagged RCT/clinical trial) but unblinded, single-network, composite endpoints
Limitations: Single research network; unblinded; the very large reported mortality effects are implausibly strong and not independently replicated.
Administration reported in studies
In the published Russian/Ukrainian literature, Epithalamin was typically given as a lyophilized peptide preparation reconstituted and administered by intramuscular injection in short repeated "courses" (commonly on the order of 5–10 daily injections per course, with courses repeated over months to years in the long-term geriatric studies). Animal studies used varied parenteral dosing and, in fly/insect work, dietary exposure. Exact human doses, course schedules, and preparation sourcing vary by study and are often incompletely reported. This is a summary of research conditions — not a dosing recommendation and not a protocol endorsed by TPC.
This section reports what published studies describe. It is not a dosing recommendation from TPS.
Safety record
The originating research groups generally described Epithalamin as well tolerated in their animal and human studies and some Russian-language reports explicitly claim a complete absence of side effects, but those claims come from the same small, mostly unblinded, single-network studies and have not been confirmed by independent safety monitoring, pharmacovigilance, or regulatory review. As an animal-tissue-derived extract, it raises additional theoretical concerns (immunogenicity, variable composition between batches, and contamination/sterility risk) that the published literature does not rigorously address. There is no established long-term safety profile in well-controlled human trials, and material sold online as "Epithalamin" or "Epitalon" is unregulated and not verified by TPC for identity, purity, or sterility. Absence of reported adverse events in small studies is not evidence of safety.
US legal status
Not FDA-approved for any use. Not on the FDA 503A compoundable bulk drug substances list, and not legally compoundable for human clinical use in the United States. Epithalamin is a foreign-origin animal-tissue peptide preparation with no US marketing authorization; in the US it appears only as a "research chemical" sold online. Vendors in that channel are unregulated and are not verified by TPC. (Note: this hub uses "TPC" — The Peptide Column.)
Open research questions
- ? Can any of the headline findings — lifespan/mortality benefit, melatonin-rhythm normalization, tumor-incidence reduction — be reproduced by independent groups outside the St. Petersburg/Kiev network in blinded, registered trials?
- ? What exactly is in the extract? Without a defined composition and batch-to-batch consistency, how can the 'active' constituents and reproducibility be verified, and how does it differ pharmacologically from the synthetic Epitalon it inspired?
- ? What is the true long-term human safety profile under modern pharmacovigilance, including immunogenicity and contamination risk from an animal-tissue-derived injectable?
- ? What are the human pharmacokinetics and bioavailability of an injected peptide mixture, and is there any plausible mechanism by which a short course produces durable multi-year effects on aging endpoints?
Get new bioregulator research as it publishes
Summaries of the Russian and English-language literature, bias-checked and plainly framed.
Subscribe Free →